Results 61 to 70 of about 55,691 (247)

Melanopsin‐Mediated Post‐Illumination Pupillary Response in Idiopathic Rapid Eye Movement (REM) Sleep Behavior Disorder and Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Aims To conduct a case–control study to investigate melanopsin‐mediated post‐illumination pupillary response (PIPR) in patients with Parkinson's disease (PD), video‐polysomnography‐confirmed isolated/idiopathic rapid eye movement (REM) sleep behavior disorder (iRBD), and age‐matched healthy controls (HC). Methods PIPR was measured at 6 s after
Joey W.Y. Chan, Bei Huang, Siyi Gong, Yuhua Yang, Shi Tang, Steven Wai‐ho Chau, Ngan Yin Chan, Tim Man‐ho Li, Yaping Liu, Anne Y.Y. Chan, Karen K.Y. Ma, Shirley X. Li, Joshua Tsoh, Kelvin K.L. Chong, Kathryn A. Roecklein, Vincent C.T. Mok, Yun Kwok Wing   +16 more
wiley   +1 more source

Advances in research on layered double hydroxides for biomedical applications

Smart Molecules, EarlyView.
Layered double hydroxides (LDHs) are pH‐responsive nanomaterials with broad biomedical applications. This review summarizes LDH synthesis methods and compares their advantages. It highlights LDHs' progress in cancer therapy, including chemo‐photothermal, chemo‐immunotherapy, and photodynamic‐immunotherapy combinations and their potential in bone repair.
Xinhui Yang, Zhiping Zhang, Zhao Wang, Hao Zhang, Yen Leng Pak, Yingying Jing, Yurong Guo, Fang Li, Xiao Wang, Quanxiang Han, Lei Yu, Xuejiao Li, Xing Gao, Jibin Song   +13 more
wiley   +1 more source

Atorvastatin action involves diminished recovery of hepatic HMG-CoA reductase activity

Journal of Lipid Research, 1998
The effects of atorvastatin on the expression of the hepatic HMG-CoA reductase and LDL receptor genes were investigated in rats. Like the other statins, atorvastatin increased the rate of degradation and presumably cycling of the hepatic LDL receptor. In
Gene C. Ness, Christopher M. Chambers, Dayami Lopez   +2 more
doaj   +1 more source

Association between CYP3A4/CYP3A5 genetic polymorphisms and treatment outcomes of atorvastatin worldwide: is there enough research on the Egyptian population?

European Journal of Medical Research, 2023
Introduction Atorvastatin is regarded as the most frequently prescribed statin worldwide for dyslipidemia. However, clinical response and risk of adverse effects to statin therapy are associated with genetic variations.
Mohammed G. Maslub, Mahasen A. Radwan, Nur Aizati Athirah Daud, Abubakar Sha’aban   +3 more
doaj   +1 more source

Solid dispersions of atorvastatin with Kolliphor RH40: enhanced supersaturation and improvement in a hyperlipidemic rat model

, 2023
Atorvastatin is a potent lipid-lowering drug with poor solubility and high presystemic clearance that limits its therapeutic efficacy. The aim of this study was to develop solid dispersions and micellar systems to obtain fastdissolving atorvastatin ...
Guarnizo Herrero, Victor, Peña Fernández, M. Ángeles, Torrado-Santiago, Santiago, Torrado Salmerón, Carlos Félix, Torre Iglesias, Paloma Marina De La, de la Torre-Iglesias, Paloma Marina, Torrado Durán, Guillermo, Peña, M. Ángeles, Guarnizo-Herrero, Víctor, Torrado Durán, Santiago, Torrado-Salmerón, Carlos, Torrado, Guillermo   +11 more
core   +1 more source

Novel reference gene microseminoprotein‐beta based prostate cancer antigen 3 urine test: Enhanced diagnostic performance for prostate cancer and feasibility of non‐digital rectal examination urine sampling

UroPrecision, EarlyView.
Abstract Background The diagnosis of prostate cancer (PCa) is limited by low specificity and invasiveness. This study aims to establish a highly accurate, noninvasive reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR)‐based urinary prostate cancer antigen 3 (PCA3) assay system and explore the feasibility of using first‐morning urine
Jianglei Xu, Lu Yang, Cong Shi, Yiwei Jiang, Jing Chen, Xiaoxiao Sun, Xuejuan Gao, Xian Wang, Jianzhong Jiang, Xiuzhi Duan, Xuchu Wang, Yiyi Xie, Zhixian Yu, Zhihua Tao, Xiaobing Dou, Chunyu Jin   +15 more
wiley   +1 more source

Atorvastatin versus tetrahydrolipstatin in male patients with dyslipidemia: A systematic review and meta-analysis [PDF]

Journal of Pharmacy & Pharmacognosy Research
Context: Atorvastatin is typically used in the treatment of dyslipidemia. However, the interest in using anti-obesity medications such as orlistat has grown rapidly as obesity is one of the variables associated with dyslipidemia.
Nur Aini Hasan, Viskasari Pintoko Kalanjati, Kusuma Eko Purwantari, Abdurachman Abdurachman, Muhammad Miftahussurur   +4 more
doaj   +1 more source

The Impact of Common Medications on Male Fertility: An Updated Systematic Review

Andrology, EarlyView.
ABSTRACT Background Compared with those of cytotoxic treatments, the potential effects of common medications on the fertility of men trying to conceive currently or planning to conceive in the future are less well described. The use of common medications may modify the gonadotropic axis, spermatogenesis, and epididymal maturation or alter male ...
Lina Jebli, Salomé Gallissian, Roxanne Barèges, Félicia Fournier, Catherine Metzler‐Guillemain, Ségolène Prades, Fanny Magnan‐Sebag, Jeanne Perrin   +7 more
wiley   +1 more source

Fenofibrate ameliorated atorvastatin and piperine-induced ROS mediated reproductive toxicity in male Wistar rats

Toxicology Reports
Atorvastatin and fenofibrate are well-known lipid-lowering drugs. Atorvastatin acts by reducing the production of cholesterol through the inhibition of the 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG Co-A reductase) enzyme, whereas fenofibrate ...
Sanjib Ghosh, Sweata Sarkar, Maharaj Biswas   +2 more
doaj   +1 more source

EFFICACY AND SAFETY OF THERAPY WITH ATORVASTATIN IN HIGH DOSES

Рациональная фармакотерапия в кардиологии, 2016
Large epidemiological trails shown that hypercholesterolemia is one of the main risk factor of ischemic heart disease (IHD). Correction of the hypercholesterolemia with GmGKoA reductase inhibitors (statins) essentially reduces IHD morbidity and mortality.
A. N. Meshkov
doaj   +1 more source